Home / Business and Economy / Apnimed IPO: Sleep Apnea Drug Aims for Nasdaq
Apnimed IPO: Sleep Apnea Drug Aims for Nasdaq
11 Jul
Summary
- Apnimed filed for an IPO, signaling a biotech market comeback.
- AD109, an oral sleep apnea treatment, met trial endpoints in May.
- FDA decision for AD109 is anticipated in early 2027.
Apnimed, a clinical-stage biopharmaceutical company, has filed for an initial public offering in the U.S. This move signals a potential resurgence in the biotech sector, which has seen renewed investor interest and capital inflow after a challenging period. The company is focused on developing oral medications for obstructive sleep apnea (OSA) and related sleep disorders.
Its lead drug candidate, AD109, is an experimental daily pill designed for OSA. In May, AD109 successfully met the primary endpoint of a late-stage clinical trial, positioning it as a promising alternative to existing device-based treatments. Apnimed has submitted a marketing application for AD109 to the U.S. Food and Drug Administration (FDA).
The company anticipates a potential FDA decision on AD109 in the first quarter of 2027. Apnimed aims to list its shares on the Nasdaq stock exchange under the symbol "APMD." Several financial institutions, including BofA Securities and Evercore ISI, are serving as underwriters for the offering.
